remdesivir drug study | Remdesivir for the Treatment of Covid-19

Keyword	CPC	PCC	Volume	Score	Length of keyword
remdesivir drug study	1.19	0.1	3649	1	21
remdesivir	0.01	0.6	4955	49	10
drug	1.32	0.9	2552	26	4
study	1.14	0.5	1030	50	5

Keyword	CPC	PCC	Volume	Score
remdesivir drug study	0.01	0.9	1443	63
remdesivir drug study scribd	1.03	0.3	2478	9

Search Results related to remdesivir drug study on Search Engine

Remdesivir for the Treatment of Covid-19 — Final Report | NEJM
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

May 22, 2020 · Remdesivir for Covid-19 — Final Report In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 ...

DA: 29 PA: 87 MOZ Rank: 5

Remdesivir | COVID-19 Treatment Guidelines
nih.gov

https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/

Feb 24, 2022 · Currently, no clinical drug-drug interaction studies of remdesivir have been conducted. In vitro, remdesivir is a minor substrate of cytochrome P450 (CYP) 3A4 and a substrate of the drug transporters organic anion transporting polypeptide (OATP) 1B1 and …

DA: 92 PA: 59 MOZ Rank: 65

Remdesivir: A Review of Its Discovery and Development Leading …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202249/

May 27, 2020 · One of the first clinical candidates that has received attention is remdesivir, a pre-existing drug candidate developed by Gilead Sciences as part of an ... NCT04321616, 2020-001052-18). 87 The comparative arms of the study are daily remdesivir, hydroxychloroquine loading dose of 800 mg × 2 followed by 400 mg × 2 daily for a total of 10 days ...

DA: 65 PA: 54 MOZ Rank: 22

Adaptive COVID-19 Treatment Trial (ACTT) - Full Text View
clinicaltrials.gov

https://clinicaltrials.gov/ct2/show/NCT04280705

Feb 21, 2020 · Drug: Remdesivir Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. ... Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid …

DA: 72 PA: 17 MOZ Rank: 80

The Strange Story Of Remdesivir, A Covid Drug That Doesn’t Work
forbes.com

https://www.forbes.com/sites/jvchamary/2021/01/31/remdesivir-covid-coronavirus/

Jan 31, 2021 · Remdesivir is an expensive drug. The drug is administered over 5 or 10 days. A five-day course of treatment costs around $2600 per person. ... In the second new study, ...

DA: 93 PA: 11 MOZ Rank: 16

Final report confirms remdesivir benefits for COVID-19
nih.gov

https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19

The antiviral drug remdesivir shortened recovery time for patients hospitalized with COVID-19, based on results from the completed trial. ... The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID). The final report appeared in the New England Journal of Medicine on October 8, 2020.

DA: 39 PA: 7 MOZ Rank: 75

Remdesivir Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/remdesivir.html

May 12, 2022 · remdesivir must be given slowly, and the infusion can take 30 to 120 minutes to complete. If you are hospitalized: remdesivir is usually given once per day for up to 10 days. If you are not hospitalized: remdesivir is usually given once per day for 3 days. You will need frequent blood tests to check your liver function.

DA: 10 PA: 38 MOZ Rank: 60

Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study …
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33354635/

Background: There are scarce data regarding the use of remdesivir in patients with severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) and end-stage renal disease as US Food and Drug Administration cautions against its use in patients with an estimated glomerular filtration rate <30 ml/min/1.73m 2 unless the potential benefits outweigh the potential risks.

DA: 72 PA: 26 MOZ Rank: 52

Design and development of an oral remdesivir derivative VV116 against
nature.com

https://www.nature.com/articles/s41422-021-00570-1

Sep 28, 2021 · Herein, we reported the discovery of an oral anti-SARS-CoV-2 nucleoside candidate, VV116, which displays favorable drug-like properties, and is going to be evaluated in clinical study for treating ...

DA: 41 PA: 75 MOZ Rank: 17

Remdesivir and three other drugs for hospitalised patients with …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060606/

May 02, 2022 · Directly randomised comparisons between one study drug and another are also included in the appendix (p 51), none of which suggested that remdesivir reduced time-to-discharge. Before IFN was discontinued for futility, 1997 patients had been concurrently randomised between it and remdesivir in hospitals where both drugs were, at that time ...

DA: 97 PA: 53 MOZ Rank: 49